ストックスクリーナーアプリを入手
1.59
26.19%
0.33
アフターアワーズ：
1.71
0.12
+7.55%
Prime Medicine Inc (PRME) 最新ニュース
Analysts Set Expectations for Prime Medicine FY2025 Earnings - Defense World
Prime Medicine’s Promising Clinical Data and Favorable Market Conditions Make It a Buy - TipRanks
Prime Medicine, Inc. (NYSE:PRME) Receives $13.14 Average Target Price from Analysts - Defense World
Prime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue Estimates - MSN
Barclays PLC Buys 12,924 Shares of Prime Medicine, Inc. (NYSE:PRME) - Defense World
Prime Medicine, Inc.: Buy Rating Backed by Promising Gene Editing Advancements and Robust Pipeline - TipRanks
Prime Medicine Reports Q1 2025 Financial Results - TipRanks
Prime Medicine Reports First Quarter 2025 Financial Results and Provides Business Updates - GlobeNewswire
Prime Medicine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Prime Medicine (PRME) Projects Funding Sufficiency Through Mid-2 - GuruFocus
Prime Medicine, Inc. SEC 10-Q Report - TradingView
PRIME MEDICINE Earnings Preview: Recent $PRME Insider Trading, Hedge Fund Activity, and More - Nasdaq
Prime Medicine Inc (PRME) Stock: A Year of Declines and Increases - investchronicle.com
Prime Medicine Inc (PRME)’s Day in Review: Closing at 1.60, Down by -3.61 - DWinneX
Stocks of Prime Medicine Inc (PRME) are poised to climb above their peers - Sete News
Is Prime Medicine Inc (PRME) a good investment opportunity? - uspostnews.com
Prime Medicine Inc (PRME) gets rating Initiated from JMP Securities - knoxdaily.com
Investor’s Delight: Prime Medicine Inc (PRME) Closes Weak at 1.41, Down -12.42 - DWinneX
Geode Capital Management LLC Raises Stock Position in Prime Medicine, Inc. (NYSE:PRME) - Defense World
Prime Medicine: Initiating Coverage At Hold With 2025 Binary Catalyst For PM359 - Seeking Alpha
Top investors say Prime Medicine Inc (PRME) ticks everything they need - Sete News
Breaking down PRME’s current quarter earnings estimates - uspostnews.com
Analysts Set Prime Medicine, Inc. (NYSE:PRME) Price Target at $13.38 - Defense World
11,426 Shares in Prime Medicine, Inc. (NYSE:PRME) Acquired by American Century Companies Inc. - Defense World
Cathie Wood's Ark Invest Offloads Uipath, Prime Medicine, And Repare Therapeutics - Benzinga
Cathie Wood's Ark Invest Offloads UiPath, Prime Medicine, And Repare Therapeutics - Benzinga
There is no way Prime Medicine Inc (PRME) can keep these numbers up - Sete News
Charles Schwab Investment Management Inc. Acquires 20,614 Shares of Prime Medicine, Inc. (NYSE:PRME) - Defense World
Prime Medicine, Inc. (NYSE:PRME) Receives Consensus Recommendation of “Buy” from Analysts - The AM Reporter
Prime Medicine, Inc. (NYSE:PRME) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Analysts Set Prime Medicine, Inc. (NYSE:PRME) Target Price at $13.38 - Defense World
Wedbush Estimates Prime Medicine FY2029 Earnings - The AM Reporter
Wedbush Forecasts Prime Medicine FY2029 Earnings - Defense World
Chardan Capital Forecasts Strong Price Appreciation for Prime Medicine (NYSE:PRME) Stock - Defense World
Prime Medicine (NYSE:PRME) Earns “Buy” Rating from HC Wainwright - Defense World
Why Prime Medicine Stock Was Climbing Higher This Week - AOL.com
Prime Medicine price target raised to $16 from $15 at Chardan - TipRanks
Chardan Raises Price Target on Prime Medicine to $16 From $15, Keeps Buy Rating -March 20, 2025 at 06:45 am EDT - MarketScreener
Why Prime Medicine Stock Is Soaring Today - Yahoo
Prime Medicine’s SWOT analysis: gene editing firm’s stock faces pivotal year - Investing.com India
Prime Medicine’s SWOT analysis: gene editing firm’s stock faces pivotal year By Investing.com - Investing.com South Africa
Prime Medicine announces new α1-antitrypsin deficiency program - BioWorld MedTech
Prime Medicine, Inc.: Promising Future in Gene Editing with Innovative AATD Program and Strategic Growth Potential - TipRanks
H.C. Wainwright maintains Buy on Prime Medicine stock, $10 target By Investing.com - Investing.com Canada
Prime Medicine, Inc.: Innovative Prime Editing Platform Targets Unmet Medical Needs with Promising Preclinical Results - TipRanks
Prime Medicine (NYSE:PRME) Given “Outperform” Rating at Wedbush - Defense World
Prime Medicine’s Promising Advancements in Liver-Targeting AATD Program with Prime Editing Technology - TipRanks
Prime Medicine advances AATD gene editing therapy - Investing.com India
Prime Medicine, Inc.: Innovative Prime Editing Technology and Promising Preclinical Results Drive Buy Rating - TipRanks
Prime Medicine Advances AATD Program With Prime Editing For Potential Curative Treatment - Nasdaq
Wedbush Adjusts Prime Medicine Price Target to $13 From $12, Maintains Outperform Rating - Marketscreener.com
Prime sets sights on liver, lung disease as next target for its gene editing tech - BioPharma Dive
Prime Medicine unveils program for treatment of AATD - TipRanks
Prime Medicine Advances AATD Program with Promising Preclinical Results - TipRanks
1.54%
7.58%
大文字化:
|
ボリューム (24 時間):